Bibliografía
1. World Health Organization. GLOBOCAN 2012: estimated cancer incidence,mortality and prevalence worldwide in 2012. Available at:http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 7-7-2014.
2. Spanish Statistical Office. Hospital Morbidity Survey. Available at:http://www.ine.es/jaxi/menu.do?type=pcaxis&path=%2Ft15%2Fp414&file=ine base&L=1 . Accessed 7-7-2014.
3. World Health Organization. World health statistics 2008. Available at:http://www.who.int/gho/publications/world_health_statistics/EN_WHS08_Full.pdf. Accessed 7-7-2014.
4. Nordlinger B, Van CE, Gruenberger T, et al. Combination of Surgery and Chemotherapy and the Role of Targeted Agents in the Treatment of Patients With Colorectal Liver Metastases: Recommendations From an Expert Panel. Ann Oncol 2009. 20: 985-92.
5. Manfredi S, Lepage C, Hatem C, et al. Epidemiology and Management of Liver Metastases From Colorectal Cancer. Ann Surg 2006. 244: 254-9.
6. Leporrier J, Maurel J, Chiche L, et al. A Population-Based Study of the Incidence, Management and Prognosis of Hepatic Metastases From Colorectal Cancer. Br J Surg 2006. 93: 465-74.
7. Heckman JE, Shore AD, Nathan H, et al. ShiftingTrends in Liver-Directed Management of Patients With Colorectal LiverMetastasis: a Population-Based Analysis. Surgery 2011. 150: 204-16.
8. Andres A, Toso C, Adam R, et al. A Survival Analysis of the Liver-First Reversed Management of Advanced Simultaneous Colorectal Liver Metastases: a LiverMetSurvey-Based Study. Ann Surg 2012. 256: 772-8.
9. Cardona K, Mastrodomenico P, D'Amico F, et al. Detailed Pathologic Characteristics of the Primary Colorectal TumorIndependently Predict Outcome After Hepatectomy for Metastases. Ann Surg Oncol 2013. 20: 148-54.
10. Aloia TA, Adam R, Azoulay D, Bismuth H, Castaing D. Outcome Following Hepatic Resection of Metastatic Renal Tumors: the Paul Brousse Hospital Experience. HPB (Oxford) 2006; 8: 100-5.
11. Kopetz S, Chang GJ, Overman MJ, et al. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 2009. 27: 3677-83.
12. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure. J Clin Oncol 2007. 25: 4575-80.
13. House MG, Ito H, Gonen M, et al. Survival After Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients During Two Decades at a Single Institution. J Am Coll Surg 2010. 210: 744-5.
14. Kanas GP, Taylor A, Primrose JN, et al. Survival After Liver Resection in Metastatic Colorectal Cancer: Review and Meta-Analysis of Prognostic Factors. Clin Epidemiol 2012. 4: 283-301.
15. Weiss MJ, D'Angelica MI. Patient Selection for Hepatic Resection for Metastatic Colorectal Cancer. J Gastrointest Oncol 2012. 3: 3-10.
16. Adams RB, Aloia TA, Loyer E, et al. Selection for Hepatic Resection of Colorectal Liver Metastases: Expert Consensus Statement. HPB (Oxford) 2013. 15: 91-103.
17. Pawlik TM, Schulick RD, Choti MA. Expanding Criteria for Resectability of Colorectal Liver Metastases. Oncologist 2008. 13: 51-64.
18. De Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250: 440-48.
19. D’Angelica M, Kornprat P, Gonen M, et al. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol 2011; 18: 1096-03.
20. Portier G, Elias D, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976–82.
21. Qing-Yang F, Ye W, Jing-Wen C et al. Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases. World J Gastroenterol 2014; 20: 4263–75.
22. Reid B. Adams, Thomas A, et al: Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013; 15: 91-103
23. Strasberg SM. Nomenclature of Hepatic Anatomy and Resections: a Review of the Brisbane 2000 System. J Hepatobiliary Pancreat Surg 2005; 12:351-5.
24. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision-making. Ann Oncol 2012; 23: 2479–16.
25. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-62.
26. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-18.
27. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience. Ann Surg 2009; 250: 187-96.
28. EA Eisenhauer, P Therasse, J Bogaerts, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228 –47.
29. Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997; 225: 51-62.
30. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479–16.
31. Adam, R; Hoti, E; Bredt, LC. Estrategias oncoquirúrgicas en el cáncer hepático metastásico. Cir Esp 2011; 89: 10-9.
32. Adam R, Levi F, Navarro F et al. Combined treatment of irresectable liver metastases of colorectal cancer by chemotherapy and subsequent hepatic resection. Br J Surg 1992; 79: S79 (abstract).
33. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94: 982-99.
34. Nishio H, Hamady ZZR, Malik HZ, et al. Outcome following repeat liver resection for colorectal liver metastases. Eur J Surg Oncol 2007; 33:729-34.
35. Luo LX, Yu ZY, Huang JW, et al. Selecting patients for a second hepatectomy for colorectal metastases: An systemic review and meta-analysis. Eur J Surg Oncol 2014:40:1036-48.
36. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94: 982-99.
37. Navarro-Freire F, Navarro-Sánchez P, García-Agua N, et al. Effectiveness of surgery in liver metastasis from colorectal cancer: experience and results of a continuous improvement process. Clin Transl Oncol. 2015;17:547-56.
38. Kanazawa A, Shiozawa M, Inagaki D, et al. Risk factors for intrahepatic recurrence after curative surgical treatment of colorectal liver metastases. Hepatogastroenterology 2010; 57:1183–86.
39. Adam R, Pascal G, Azoulay D, et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003; 238:871–83.
40. Belghiti J, Guevara OA, Noun R, et al. Liver hanging maneuver: a safe approach to right hepatectomy without liver mobilization. J Am Coll Surg 2001; 193:109–11.
41. Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94:274–86.
42. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118-24.
43. Lopez P, Marzano E, Piardi T, et al. Repeat hepatectomy for Liver metastases from colorrectal primary cancer: A review of the literature. J Visc Surg 2012; 149:97-9.
44. Langenhoff BS, Krabbe PF, Ruers TJ. Efficacy of Follow-Up After Surgical Treatment of Colorectal Liver Metastases. Eur J Surg Oncol 2009. 35: 180-6.
45. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009;27:3385–90.
46. Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012; 17: 1225-39.